Annual Cash & Cash Equivalents
$31.79 M
-$24.45 M-43.47%
30 April 2024
Summary:
KalVista Pharmaceuticals annual cash & cash equivalents is currently $31.79 million, with the most recent change of -$24.45 million (-43.47%) on 30 April 2024. During the last 3 years, it has fallen by -$18.80 million (-37.17%). KALV annual cash & cash equivalents is now -43.47% below its all-time high of $56.24 million, reached on 30 April 2023.KALV Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$31.85 M
+$59.00 K+0.19%
31 July 2024
Summary:
KalVista Pharmaceuticals quarterly cash and cash equivalents is currently $31.85 million, with the most recent change of +$59.00 thousand (+0.19%) on 31 July 2024. Over the past year, it has dropped by -$25.82 million (-44.77%). KALV quarterly cash and cash equivalents is now -73.70% below its all-time high of $121.12 million, reached on 31 October 2018.KALV Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KALV Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.5% | -44.8% |
| 3 y3 years | -37.2% | -31.5% |
| 5 y5 years | -0.7% | +46.6% |
KALV Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -43.5% | +3.4% | -62.5% | +38.1% |
| 5 y | 5 years | -43.5% | +101.3% | -62.5% | +101.7% |
| alltime | all time | -43.5% | +715.7% | -73.7% | +901.2% |
KalVista Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| July 2024 | - | $31.85 M(+0.2%) |
| Apr 2024 | $31.79 M(-43.5%) | $31.79 M(+37.9%) |
| Jan 2024 | - | $23.06 M(-60.0%) |
| Oct 2023 | - | $57.67 M(+16.7%) |
| July 2023 | - | $49.41 M(-12.1%) |
| Apr 2023 | $56.24 M(+83.0%) | $56.24 M(-33.9%) |
| Jan 2023 | - | $85.05 M(+120.4%) |
| Oct 2022 | - | $38.59 M(+1.9%) |
| July 2022 | - | $37.86 M(+23.2%) |
| Apr 2022 | - | $30.73 M(-32.6%) |
| Apr 2022 | $30.73 M(-39.3%) | - |
| Jan 2022 | - | $45.58 M(-2.0%) |
| Oct 2021 | - | $46.49 M(-3.8%) |
| July 2021 | - | $48.34 M(-4.4%) |
| Apr 2021 | $50.59 M(+220.4%) | $50.59 M(+185.4%) |
| Jan 2021 | - | $17.73 M(+9.6%) |
| Oct 2020 | - | $16.17 M(-10.2%) |
| July 2020 | - | $18.01 M(+14.1%) |
| Apr 2020 | $15.79 M(-50.7%) | $15.79 M(-15.2%) |
| Jan 2020 | - | $18.61 M(-14.3%) |
| Oct 2019 | - | $21.72 M(-27.9%) |
| July 2019 | - | $30.11 M(-5.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Apr 2019 | $32.01 M(-37.3%) | $32.01 M(-43.2%) |
| Jan 2019 | - | $56.34 M(-53.5%) |
| Oct 2018 | - | $121.12 M(+152.0%) |
| July 2018 | - | $48.07 M(-5.8%) |
| Apr 2018 | $51.05 M(+65.0%) | $51.05 M(-13.0%) |
| Jan 2018 | - | $58.68 M(+108.6%) |
| Oct 2017 | - | $28.13 M(+6.3%) |
| July 2017 | - | $26.46 M(-14.5%) |
| Apr 2017 | $30.95 M(+42.2%) | $30.95 M(-7.6%) |
| Jan 2017 | - | $33.50 M(-4.9%) |
| Sept 2016 | - | $35.21 M(-4.4%) |
| June 2016 | - | $36.82 M(-24.0%) |
| Apr 2016 | $21.76 M(-59.5%) | - |
| Mar 2016 | - | $48.45 M(-9.8%) |
| Dec 2015 | $53.72 M(+1278.6%) | $53.72 M(-10.3%) |
| Sept 2015 | - | $59.88 M(-8.4%) |
| June 2015 | - | $65.38 M(+1955.4%) |
| Mar 2015 | - | $3.18 M(-18.4%) |
| Dec 2014 | $3.90 M(-60.2%) | $3.90 M(-58.2%) |
| Sept 2014 | - | $9.32 M(-4.7%) |
| Dec 2013 | $9.78 M(+18.7%) | $9.78 M |
| Dec 2012 | $8.24 M | - |
FAQ
- What is KalVista Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is KalVista Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is KalVista Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of KALV is $31.79 M
What is the all time high annual cash & cash equivalents for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high annual cash & cash equivalents is $56.24 M
What is KalVista Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, KALV annual cash & cash equivalents has changed by -$24.45 M (-43.47%)
What is KalVista Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of KALV is $31.85 M
What is the all time high quarterly cash and cash equivalents for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high quarterly cash and cash equivalents is $121.12 M
What is KalVista Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, KALV quarterly cash and cash equivalents has changed by -$25.82 M (-44.77%)